AstraZeneca’s LATIFY Phase III Trial of Ceralasertib Misses Primary Endpoint in Lung Cancer Study 
U.S. Lawmakers Urge Pentagon to Blacklist More Chinese Tech Firms Over Military Ties 
Maersk Vessel Successfully Transits Red Sea After Nearly Two Years Amid Ongoing Security Concerns 
Roche CEO Warns US Drug Price Deals Could Raise Costs of New Medicines in Switzerland 
FDA Fast-Tracks Approval of Altria’s on! PLUS Nicotine Pouches Under New Pilot Program 
Google and Apple Warn U.S. Visa Holders to Avoid International Travel Amid Lengthy Embassy Delays 
Elliott Management Takes $1 Billion Stake in Lululemon, Pushes for Leadership Change 
JPMorgan’s Top Large-Cap Pharma Stocks to Watch in 2026 
Delta Air Lines President Glen Hauenstein to Retire, Leaving Legacy of Premium Strategy 
Italy Fines Apple €98.6 Million Over App Store Dominance 
Elon Musk Wins Reinstatement of Historic Tesla Pay Package After Delaware Supreme Court Ruling 
Toyota to Sell U.S.-Made Camry, Highlander, and Tundra in Japan From 2026 to Ease Trade Tensions 
Trump Administration Reviews Nvidia H200 Chip Sales to China, Marking Major Shift in U.S. AI Export Policy 
Uber and Baidu Partner to Test Robotaxis in the UK, Marking a New Milestone for Autonomous Ride-Hailing 
7-Eleven CEO Joe DePinto to Retire After Two Decades at the Helm 
Oracle Stock Surges After Hours on TikTok Deal Optimism and OpenAI Fundraising Buzz 
 over alleged Violations of Securities Laws announced by Shareholders Foundation - EconoTimes)
SAN DIEGO, Dec. 07, 2016 -- The Shareholders Foundation, Inc. announces that a lawsuit was filed in Pennsylvania on behalf of certain purchasers of shares of Lannett Company, Inc. (NYSE:LCI) over alleged Securities Laws Violations by Lannett Company.
Investors, who purchased shares of Lannett Company, Inc. (NYSE:LCI) in August 2013 or earlier and currently hold any of those NYSE:LCI shares, have also certain options and should contact the Shareholders Foundation at [email protected] or call +1(858) 779 - 1554.
The plaintiff alleges that the defendants made allegedly false and/or misleading statements and/or failed to disclose that Lannett Company, Inc. was fixing, maintaining, and controlling prices of digoxin in violation of Connecticut antitrust laws, that Lannett Company, Inc. was allocating and dividing customers and territories with competitors relating to the sale of digoxin in violation of Connecticut antitrust laws, that Lannett Company, Inc.’s anticompetitive practices subjected Lannett to heightened regulatory scrutiny, including possible investigation by the Connecticut Office of the Attorney General ("CTAG"), and that as a result of the foregoing, Lannett Company, Inc.'s public statements were allegedly materially false and misleading at all relevant times.
Those who purchased Lannett Company, Inc. (NYSE:LCI) shares should contact the Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio legal monitoring and a settlement claim filing service, which does research related to shareholder issues and informs investors of securities class actions, settlements, judgments, and other legal related news to the stock/financial market. The Shareholders Foundation, Inc. is not a law firm. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.
CONTACT: Shareholders Foundation, Inc.
Michael Daniels
+1 (858) 779-1554
[email protected]
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
